Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IOS-6071
- Development stage
- Preclinical
- Lead developer
- ImmunOs Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
IOS-6071 is a preclinical-stage antibody being developed by ImmunOs Therapeutics for the treatment of inflammatory diseases. It utilizes the company's proprietary HLA-based platform to target the HLA-E/NKG2A axis. By modulating the interaction between HLA-E and the inhibitory receptor NKG2A, IOS-6071 aims to regulate inflammatory immune responses. This approach leverages the natural role of HLA molecules in immune signaling to restore balance in autoimmune and inflammatory conditions.
Beyond the preview
Go deeper on IOS-6071.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IOS-6071.